Chronic inflammation drives disease – but how can it be measured?

Chronic inflammation is a driver of disease development, disease progression and outcome. Chronic inflammation is derived from lifestyle factors (diet, smoking exercise), genetics and environmental factors (polition, chemicals etc). Also, social factors (e.g. looniness) and stressors (e.g. life stressors such as divorce, bankruptcy, and adverse events in childhood).

But how do you measure chronic inflammation? Traditionally, chronic inflammation has been measured using C-reactive protein (CRP). However, CRP is a fluctuating molecule affected by banal infections and is not sensitive enough to fully capture chronic inflammation.

In comes suPAR. suPAR is a newer biomarker which may, in fact, be a biomarker of chronic inflammation since it is stably associated with inflammation and immune activation; shares the same risk factors as many age-related diseases; is both elevated by and predicts age-related diseases. There is strong evidence that suPAR is a prognostic marker of adverse events, morbidity, and mortality. It is associated with immune activity and prognosis across diverse conditions, including kidney disease, cardiovascular disease, cancer, diabetes, and inflammatory disorders.

All individuals have a basic suPAR level

which simplifies statistics

suPAR is a measure of chronic inflammation

and is involved in both development and progression of disease

A high level of chronic inflammation is consistently a significant predictor of adverse outcomes

also when adjusting for other variables such as age, sex and disease and other biomarkers

suPAR is an inflammatory biomarker that predicts patient outcomes​

suPAR

suPAR is a naturally occurring protein in human blood​

suPAR reflects the immune system’s activation level​

suPAR predicts negative patient outcomes across diseases

suPAR is a stable, unspecific biomarker across diseases​

suPAR is prognostic in more than 20 disease areas

In the general population, individuals with low suPAR age slower

Low suPAR individuals have lower risk of developing diabetes, cardiovascular disease, cancer, and organ failure

In longevity Lifespan is often understood as the number of years in one's life, while healthspan is the quality of those years”

Documented by 1000+ peer-reviewed publications

Here you can find a summary of the research done on suPAR within different disease areas.

“Wanted to share with you our latest study comparing suPAR assays. It places ViroGates suPARnostic® as the gold standard for measuring suPAR (1)”

– Dr. Salim Hayek, Vice President & Chief Transformation Officer at the University of Texas Medical Branch
Author of two New England Journal of Medicine papers about suPAR (2,3)

1: Vasbinder, A. et al. Assay-related differences in SuPAR levels: implications for measurement and data interpretation. Journal of nephrology, 2023, 36(1), 157–159.
2: Hayek, S., et al. Soluble urokinase receptor and chronic kidney disease. New England Journal of Medicine, 2015, 373(20), 1916-1925.
3: Hayek, S., et al. Soluble urokinase receptor and acute kidney injury. New England Journal of Medicine, 2020, 382(5), 416-426.

1000+

published suPAR studies in leading medical journals

Nature Medicine Logo
Science Journal Logo
JAMA Pediatrics Logo

The suPARnostic® brand consists of four products:

suPARnostic POC+

Quick Triage

A Point of Care Solution

TurbiLatex

For Automated Systems

ELISA Assay

Clinical and Research

POC+

Point-of-care finger prick

New Webinar

Webinar

Catch COVID-19

-Improve your triage

Sign up to view webinar recording

View recording

suPARnostic® by ViroGates